HYDERABAD, India–(BUSINESS WIRE)–#AnalyticalDevelopment–Sai Life Sciences Limited (BSE: 544306 | NSE: SAILIFE), one of India’s leading integrated contract researchHYDERABAD, India–(BUSINESS WIRE)–#AnalyticalDevelopment–Sai Life Sciences Limited (BSE: 544306 | NSE: SAILIFE), one of India’s leading integrated contract research

Sai Life Sciences to Recruit 700+ Professionals in FY27

2026/02/20 17:15
3 min read
For feedback or concerns regarding this content, please contact us at crypto.news@mexc.com

HYDERABAD, India–(BUSINESS WIRE)–#AnalyticalDevelopment–Sai Life Sciences Limited (BSE: 544306 | NSE: SAILIFE), one of India’s leading integrated contract research, development and manufacturing organizations (CRDMOs), today announced plans to hire 700+ scientific, technical, and management professionals during 2026–27 as it scales capabilities to meet growing global demand for end-to-end drug discovery, development and manufacturing services.

The recruitment will span roles across medicinal chemistry, biology, DMPK, process and analytical development, formulation development, process engineering, technology transfer, quality, peptides, business development, program management, and manufacturing, among others.

A specific area of focus through this recruitment drive will be on attracting high-calibre scientists from leading institutions in India and globally, reflecting the increasing complexity of programs being entrusted to Sai Life Sciences and the higher scientific expectations placed on Indian CRDMOs by global innovator companies.

Making the announcement, Krishna Kanumuri, CEO & Managing Director, Sai Life Sciences, said: “We are at an inflection point for the Indian CRDMO industry. Global supply-chain rebalancing, the need for resilient development and manufacturing partners, and the rising sophistication of outsourced science are converging in India’s favour. Demand for high-quality, integrated partners is already visible, and this expansion is about preparing ourselves to serve that demand at scale — with the right infrastructure, strong digital and quality systems, and deep scientific capability.”

Krishna added, “For scientists, this is a genuinely exciting moment. They have the opportunity to work on globally relevant, high-impact programs while being based in India. We believe this phase of growth creates a compelling opportunity for Indian scientists anywhere in the world to consider building the next chapter of their careers here—without compromising on scientific rigor, exposure, or the quality of work.”

The new roles will support growing activity in areas such as complex small-molecule synthesis, high-throughput experimentation, data-enabled drug discovery, and late-stage CMC and commercial manufacturing scale-up.

As part of its talent strategy, Sai Life Sciences has launched a global alumni engagement platform and is strengthening learning, leadership development, and internal mobility programs to support long-term career growth.

Sai Life Sciences operates across India, the UK, and the US, serving global pharmaceutical and biotechnology companies. Its Manchester site focuses on process R&D, while its Boston Biology facility supports early discovery collaborations and client engagement. The majority of new roles will be based in Hyderabad, home to the company’s largest integrated R&D campus. With more than 3,400 scientists and professionals currently on board, the planned hiring reflects its continued growth and its expanding role as a global CRDMO partner.

About Sai Life Sciences

Sai Life Sciences is a full-service CRDMO working with innovator pharma and biotech companies globally to accelerate the discovery, development, and commercialization of small molecules. With operations across India, the UK, and the US, Sai Life Sciences offers scientific expertise, world-class infrastructure, and a culture of excellence focused on quality, safety, and sustainability. www.sailife.com

Contacts

For further information, contact:

Sriram Gopalakrishnan
Vice President, Corporate Communications
Sai Life Sciences  
Ph: +91 9121295355
sriram.g@sailife.com

Market Opportunity
Sharpe AI Logo
Sharpe AI Price(SAI)
$0.0009644
$0.0009644$0.0009644
-0.40%
USD
Sharpe AI (SAI) Live Price Chart

AI Strategy: Powered 24/7

AI Strategy: Powered 24/7AI Strategy: Powered 24/7

Generate automated strategies using natural language

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact crypto.news@mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Binance Perpetual Futures Revolution: QQQ and Major US Stocks Enter Crypto Derivatives Market with 10x Leverage

Binance Perpetual Futures Revolution: QQQ and Major US Stocks Enter Crypto Derivatives Market with 10x Leverage

BitcoinWorld Binance Perpetual Futures Revolution: QQQ and Major US Stocks Enter Crypto Derivatives Market with 10x Leverage In a groundbreaking move that bridges
Share
bitcoinworld2026/04/02 18:00
Franklin Templeton CEO Dismisses 50bps Rate Cut Ahead FOMC

Franklin Templeton CEO Dismisses 50bps Rate Cut Ahead FOMC

The post Franklin Templeton CEO Dismisses 50bps Rate Cut Ahead FOMC appeared on BitcoinEthereumNews.com. Franklin Templeton CEO Jenny Johnson has weighed in on whether the Federal Reserve should make a 25 basis points (bps) Fed rate cut or 50 bps cut. This comes ahead of the Fed decision today at today’s FOMC meeting, with the market pricing in a 25 bps cut. Bitcoin and the broader crypto market are currently trading flat ahead of the rate cut decision. Franklin Templeton CEO Weighs In On Potential FOMC Decision In a CNBC interview, Jenny Johnson said that she expects the Fed to make a 25 bps cut today instead of a 50 bps cut. She acknowledged the jobs data, which suggested that the labor market is weakening. However, she noted that this data is backward-looking, indicating that it doesn’t show the current state of the economy. She alluded to the wage growth, which she remarked is an indication of a robust labor market. She added that retail sales are up and that consumers are still spending, despite inflation being sticky at 3%, which makes a case for why the FOMC should opt against a 50-basis-point Fed rate cut. In line with this, the Franklin Templeton CEO said that she would go with a 25 bps rate cut if she were Jerome Powell. She remarked that the Fed still has the October and December FOMC meetings to make further cuts if the incoming data warrants it. Johnson also asserted that the data show a robust economy. However, she noted that there can’t be an argument for no Fed rate cut since Powell already signaled at Jackson Hole that they were likely to lower interest rates at this meeting due to concerns over a weakening labor market. Notably, her comment comes as experts argue for both sides on why the Fed should make a 25 bps cut or…
Share
BitcoinEthereumNews2025/09/18 00:36
XRP Turns Bearish After Failing to Break $1.36 Resistance – Key Support at $1.30 in Focus

XRP Turns Bearish After Failing to Break $1.36 Resistance – Key Support at $1.30 in Focus

BitcoinWorld XRP Turns Bearish After Failing to Break $1.36 Resistance – Key Support at $1.30 in Focus XRP, the digital asset associated with Ripple, is facing
Share
bitcoinworld2026/05/26 13:40

No Chart Skills? Still Profit

No Chart Skills? Still ProfitNo Chart Skills? Still Profit

Copy top traders in 3s with auto trading!